Computational drug design, synthesis, acetylcholinesterase inhibition and kinetic evaluation of novel benzothiazole-thiadiazole/oxadiazole derivatives.
{"title":"Computational drug design, synthesis, acetylcholinesterase inhibition and kinetic evaluation of novel benzothiazole-thiadiazole/oxadiazole derivatives.","authors":"Ramesh Ambatwar, Pooja Singh, Suman Ghosh, Lokesh Chandrakar, Ashok Kumar Datusalia, Gopal L Khatik","doi":"10.1080/17568919.2026.2739927","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Developing novel benzothiazole-thiadiazole & oxadiazole hybrids as acetylcholinesterase (AChE) inhibitors.</p><p><strong>Material and methods: </strong>Benzothiazole-thiadiazole (<b>10a-n</b>) and benzothiazole-oxadiazole (<b>11a-p</b>) hybrids were synthesized and evaluated for AChE inhibition. The drug-likeness, molecular docking, molecular dynamics simulations, and cytotoxicity were also performed.</p><p><strong>Results: </strong>Compounds <b>10b</b>, <b>10d</b> and <b>10j</b> emerged as potent inhibitors, displaying IC<sub>50</sub> 0.05 µM, 0.12 µM and 0.14 µM, respectively. The IC<sub>50</sub> of compounds <b>11c</b>, <b>11f</b> and <b>11n</b> are 0.13 µM, 0.11 µM, and 0.09 µM, respectively, which are comparable to donepezil (IC<sub>50</sub> 0.03 µM). Further enzyme kinetic assays revealed a competitive inhibition mechanism. Drug-likeness, molecular docking and molecular dynamic simulation and cytotoxicity assays confirm the efficacy and safety profile.</p><p><strong>Conclusions: </strong>Benzothiazole-thiadiazole & oxadiazole scaffolds are promising leads for the developing AChE inhibitors.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"2859-2876"},"PeriodicalIF":3.3000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652075/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17568919.2026.2739927","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Material and methods: Benzothiazole-thiadiazole (10a-n) and benzothiazole-oxadiazole (11a-p) hybrids were synthesized and evaluated for AChE inhibition. The drug-likeness, molecular docking, molecular dynamics simulations, and cytotoxicity were also performed.
Results: Compounds 10b, 10d and 10j emerged as potent inhibitors, displaying IC50 0.05 µM, 0.12 µM and 0.14 µM, respectively. The IC50 of compounds 11c, 11f and 11n are 0.13 µM, 0.11 µM, and 0.09 µM, respectively, which are comparable to donepezil (IC50 0.03 µM). Further enzyme kinetic assays revealed a competitive inhibition mechanism. Drug-likeness, molecular docking and molecular dynamic simulation and cytotoxicity assays confirm the efficacy and safety profile.
Conclusions: Benzothiazole-thiadiazole & oxadiazole scaffolds are promising leads for the developing AChE inhibitors.
期刊介绍:
Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.